AIM ImmunoTech Inc

ASE:AIM   3:59:59 PM EDT
2.06
0.00 (0.00%)
Products

Aim Immunotech Announces Positive Safety Data In Second Cohort Of Phase 1 Clinical Study Investigating Intranasal Administration Of Ampligen As A Potential Prophylaxis Or Treatment For Covid-19

Published: 04/27/2021 11:42 GMT
AIM ImmunoTech Inc (AIM) - Aim Immunotech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen As a Potential Prophylaxis Or Treatment for Covid-19 and Other Respiratory Viral Diseases.
Aim Immunotech Inc - Study Will Proceed With Enrollment Into Cohort 3.
Aim Immunotech Inc - Completed Dosing of Cohort 2 in Phase 1 Clinical Study of Ampligen As an Intranasal Therapy, Reporting No Serious Adverse Events.